Telix Pharmaceuticals Limited (TLX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Telix Pharmaceuticals Limited stock (TLX) is currently trading at $8.77. Telix Pharmaceuticals Limited PE ratio is 475.50. Telix Pharmaceuticals Limited PS ratio (Price-to-Sales) is 3.69. Analyst consensus price target for TLX is $20.89. WallStSmart rates TLX as Sell.
- TLX PE ratio analysis and historical PE chart
- TLX PS ratio (Price-to-Sales) history and trend
- TLX intrinsic value — DCF, Graham Number, EPV models
- TLX stock price prediction 2025 2026 2027 2028 2029 2030
- TLX fair value vs current price
- TLX insider transactions and insider buying
- Is TLX undervalued or overvalued?
- Telix Pharmaceuticals Limited financial analysis — revenue, earnings, cash flow
- TLX Piotroski F-Score and Altman Z-Score
- TLX analyst price target and Smart Rating
Telix Pharmaceuticals
📊 No data available
Try selecting a different time range
TLX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Telix Pharmaceuticals Limited (TLX)
TLX trades 4850% above its Graham fair value of $0.14, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Telix Pharmaceuticals Limited (TLX) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Telix Pharmaceuticals Limited (TLX) Key Strengths (2)
Revenue surging 58.90% year-over-year
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Telix Pharmaceuticals Limited (TLX) Areas to Watch (6)
Losing money on operations
Very low returns on shareholder equity
Very expensive at 7.1x book value
Very thin margins, barely profitable
Very low institutional interest at 0.14%
Revenue is fairly priced at 3.69x sales
Supporting Valuation Data
Telix Pharmaceuticals Limited (TLX) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.5/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 58.90%.
The Bear Case
The primary concerns are Operating Margin, Return on Equity, Price/Book. Some valuation metrics including Price/Sales (3.69), Price/Book (7.14) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 3.14%, Operating Margin at -0.30%, Profit Margin at 1.63%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 3.14% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 58.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TLX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TLX's Price-to-Sales ratio of 3.69x trades 31% below its historical average of 5.36x (33th percentile). The current valuation is 66% below its historical high of 10.99x set in Nov 2024, and 83% above its historical low of 2.01x in Feb 2026. Over the past 12 months, the PS ratio has compressed from ~7.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Telix Pharmaceuticals Limited (TLX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Telix Pharmaceuticals Limited is a strong growth company balancing expansion with improving profitability. Revenue reached 664M with 59% growth year-over-year. Profit margins are strong at 163.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 59% YoY, reaching 664M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 314.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Free cash flow is -93M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Telix Pharmaceuticals Limited maintain 59%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 475.5x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Telix Pharmaceuticals Limited.
Bottom Line
Telix Pharmaceuticals Limited offers an attractive blend of growth (59% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:09 AM
About Telix Pharmaceuticals Limited(TLX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company is headquartered in North Melbourne, Australia.